Q4 2024 · 13F-HR
Flagship Pioneering, LLCholdings as filed
Filed 2025-02-14 · accession 0000950123-25-002708
$334.2M
Reported value
5
Positions
2024-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 60770K107 | MRNA | Moderna Inc | $192.6M | 57.6% | 4,632,149 | Common | SHARED |
| 344174107 | FHTX | Foghorn Therapeutics Inc | $59.8M | 17.9% | 12,674,120 | Common | SHARED |
| 799566104 | SANA | Sana Biotechnology Inc | $40.8M | 12.2% | 25,001,856 | Common | SHARED |
| 68217N105 | — | Omega Therapeutics Inc | $21.8M | 6.52% | 29,225,579 | Common | SHARED |
| 81750R102 | MCRB1EUR | Seres Therapeutics Inc | $19.3M | 5.76% | 23,117,045 | Common | SHARED |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.